Multiplex biomarkers in blood

Alzheimer's Research and Therapy

Volumn 5, Issue 3, 2013, Pages

  Gupta, Veer Bala ^a   Sundaram, Ramani ^b   Martins, Ralph N ^a,c,d  

^a EDITH COWAN UNIVERSITY   (Australia)

^b Centre for Ageing and Alzheimer's   (India)

^c HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^d Hollywood Medical Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; INTERLEUKIN 17; INTERLEUKIN 6; SOMATOMEDIN BINDING PROTEIN 2; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; BLOOD ANALYSIS; EARLY DIAGNOSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84879565988     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt185     Document Type: Review

References (51)

1. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Knopman DS, Alzheimer's Disease Neuroimaging Initiative, Arch Neurol 2012 69 856 867 10.1001/archneurol.2011.3405 22409939
2. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH, Alzheimers Dement 2011 7 280 292 10.1016/j.jalz.2011.03.003 21514248
3. Biomarkers of Alzheimer disease in plasma. Irizarry MC, NeuroRx 2004 1 226 234 10.1602/neurorx.1.2.226 15717023 (Pubitemid 46591884)
4. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, AIBL Research Group, J Alzheimers Dis 2010 20 1233 1242 20413897
5. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD, Ann Neurol 1999 46 412 416 10.1002/1531-8249(199909)46: 3<412::AID-ANA19>3.0.CO;2-A 10482274 (Pubitemid 29416281)
6. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, Shoji S, J Neurol Sci 1996 141 65 68 10.1016/0022-510X(96)00143-8 8880695 (Pubitemid 26297732)
7. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M, Neurology 2004 63 828 831 10.1212/01.WNL. 0000137040.64252.ED 15365131 (Pubitemid 39297642)
8. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC, Arch Neurol 2003 60 958 964 10.1001/archneur.60.7.958 12873852 (Pubitemid 36858355)
9. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S, Nat Med 1996 2 864 870 10.1038/nm0896-864 8705854 (Pubitemid 26296755)
10. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, Asami-Odaka A, Fukushima T, Imai K, Iwatsubo T, Neurology 1997 48 741 745 10.1212/WNL.48.3.741 9065558 (Pubitemid 27120117)
11. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Blasko I, Kemmler G, Krampla W, Jungwirth S, Wichart I, Jellinger K, Tragl KH, Fischer P, Neurobiol Aging 2005 26 1135 1143 10.1016/j.neurobiolaging.2005.03.006 15917096 (Pubitemid 40726005)
12. The lzheimer's disease signature potential perspectives for novel biomarkers. Davinelli S, Intrieri M, Russo C, Di Costanzo A, Zella D, Bosco P, Scapagnini G, Immun Ageing 2011 8 7 10.1186/1742-4933-8-7 21933389
13. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettenati C, Mussi M, Parrinello G, Cottini E, Lenzi GL, Trabucchi M, Cattabeni F, Di Luca M, Neurology 2001 57 2243 2248 10.1212/WNL.57.12.2243 11756604 (Pubitemid 34016458)
14. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN, AIBL Research Group, Neurology 2011 76 1091 1098 10.1212/WNL.0b013e318211c352 21422459
15. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Alzheimer's Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM, Hum Mol Genet 2012 21 4558 4571 10.1093/hmg/dds296 22821396
16. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A, BMJ 2001 322 1447 1451 10.1136/bmj.322.7300.1447 11408299 (Pubitemid 32575406)
17. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD, Neurology 2001 57 1447 1452 10.1212/WNL.57.8.1447 11673587 (Pubitemid 32995727)
18. Statins and the risk of dementia. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA, Lancet 2000 356 1627 1631 10.1016/S0140-6736(00)03155-X 11089820
19. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I, Arch Neurol 2002 59 223 227 10.1001/archneur.59.2.223 11843693 (Pubitemid 34240938)
20. Oxysterols and neurodegenerative diseases. Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S, Mol Aspects Med 2009 30 171 179 10.1016/j.mam.2009.02.001 19248803
21. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Bretillon L, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crisby M, Hillert J, Groth CG, Diczfalusy U, Bjorkhem I, Neurosci Lett 2000 293 87 90 10.1016/S0304-3940(00)01466-X 11027840
22. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R, J Psychiatr Res 2002 36 27 32 10.1016/S0022-3956(01)00050-4 11755458 (Pubitemid 34037845)
23. Cerebrospinal fluid 24Shydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schroder J, Neurosci Lett 2002 324 83 85 10.1016/S0304-3940(02)00164-7 11983301 (Pubitemid 34442684)
24. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Bjorkhem I, J Lipid Res 2003 44 793 799 10.1194/jlr.M200434-JLR200 12562838 (Pubitemid 37279681)
25. Mitochondrial involvement in Alzheimer's disease. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA, Biochim Biophys Acta 1999 1410 171 182 10.1016/S0005-2728(98)00165-0 10076025 (Pubitemid 29078603)
26. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Butterfield DA, Castegna A, Lauderback CM, Drake J, Neurobiol Aging 2002 23 655 664 10.1016/S0197-4580(01)00340-2 12392766 (Pubitemid 35217687)
27. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ, Ann Neurol 1998 44 410 413 10.1002/ana.410440322 9749613 (Pubitemid 28421451)
28. Increased CSF F2-isoprostane concentration in probable AD. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD, Neurology 1999 52 562 565 10.1212/WNL.52.3.562 10025788 (Pubitemid 29075604)
29. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P, Neurobiol Aging 2006 27 394 401 10.1016/j.neurobiolaging.2005.07.003 16125823 (Pubitemid 43185324)
30. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D, J Neurol 2007 254 1666 1675 10.1007/s00415-007-0610-z 17994313
31. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA, Ann Neurol 2000 48 809 812 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9 11079549
32. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ, Arch Neurol 2002 59 972 976 10.1001/archneur.59.6.972 12056933 (Pubitemid 34640757)
33. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, Rayssiguier Y, Jalenques I, Mazur A, Free Radic Biol Med 1999 27 463 469 10.1016/S0891-5849(99)00096-9 10468223 (Pubitemid 29395442)
34. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D, Neurodegener Dis 2007 4 403 405 10.1159/000107699 17934322 (Pubitemid 47557280)
35. Biochemical markers and risk factors of Alzheimer's disease. Flirski M, Sobow T, Curr Alzheimer Res 2005 2 47 64 10.2174/1567205052772704 15977989 (Pubitemid 41389259)
36. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C, Neurobiol Aging 2002 23 485 508 10.1016/S0197-4580(01)00328-1 12009495 (Pubitemid 34495461)
37. Proteome-based plasma biomarkers for Alzheimer's disease. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S, Brain 2006 129 3042 3050 10.1093/brain/awl279 17071923 (Pubitemid 44684524)
38. Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. Ueno I, Sakai T, Yamaoka M, Yoshida R, Tsugita A, Electrophoresis 2000 21 1832 1845 10.1002/(SICI)1522-2683(20000501)21:9<1832::AID-ELPS1832>3.0.CO;2-7 10870969 (Pubitemid 30394875)
39. Serum biomarkers for Alzheimer's disease: proteomic discovery. German DC, Gurnani P, Nandi A, Garner HR, Fisher W, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP, Biomed Pharmacother 2007 61 383 389 10.1016/j.biopha.2007.05.009 17614251 (Pubitemid 47239345)
40. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T, Nat Med 2007 13 1359 1362 10.1038/nm1653 17934472 (Pubitemid 350073592)
41. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group, Arch Neurol 2012 69 1318 1325 10.1001/archneurol.2012.1282 22801742
42. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging Initiative, Neurology 2012 79 897 905 10.1212/WNL.0b013e318266fa70 22855860
43. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. Butterfield DA, Boyd-Kimball D, Castegna A, J Neurochem 2003 86 1313 1327 10.1046/j.1471-4159.2003.01948.x 12950441 (Pubitemid 37174249)
44. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC, Proteomics 2003 3 1486 1494 10.1002/pmic.200300470 12923774 (Pubitemid 37048074)
45. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH, Ann Neurol 2007 61 120 129 10.1002/ana.21038 17167789 (Pubitemid 46363839)
46. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, PLoS One 2011 6 28092 10.1371/journal.pone.0028092 22163278
47. Elucidating the role of metals in Alzheimer's disease through the use of Surface-Enhanced Laser Desorption/Ionisation time-of-flight mass spectrometry. Watt AD, Perez KA, Hung LW, Methods Mol Biol 2011 752 229 240 10.1007/978-1-60327-223-0-15 21713641
48. Mining biomarkers in human sera using proteomic tools. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, Kupchak P, Kireeva I, Ingratta L, Jackowski G, Proteomics 2004 4 244 256 10.1002/pmic.200300495 14730686 (Pubitemid 38140889)
49. Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study. Henkel AW, Muller K, Lewczuk P, Muller T, Marcus K, Kornhuber J, Wiltfang J, J Neural Transm 2012 119 779 788 10.1007/s00702-012-0781-3 22415063
50. Identification of oxidized plasma proteins in Alzheimer's disease. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW, Biochem Biophys Res Commun 2002 293 1566 1570 10.1016/S0006-291X(02)00420-5 12054695 (Pubitemid 34681057)
51. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, DiCesare J, Denoyer E, Patton WF, Ediger R, Sapp L, Ziegert T, Lynch C, Kramer S, Whiteley GR, Wall MR, Mannion DP, Della Cioppa G, Rakitan JS, Wolfe GM, Clin Chem 2005 51 1946 1954 10.1373/clinchem.2005.053090 16081505 (Pubitemid 41368194)